» Articles » PMID: 33308233

Heart Failure Documentation in Outpatients with Diabetes and Volume Overload: an Observational Cohort Study from the Diabetes Collaborative Registry

Overview
Publisher Biomed Central
Date 2020 Dec 14
PMID 33308233
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Heart failure is a common and devastating complication of type 2 diabetes (T2D). Prompt recognition of heart failure may avert hospitalization, facilitate use of guideline-directed therapies, and impact choice of T2D medications. We sought to determine the rate and factors associated with heart failure documentation in T2D patients with evidence of volume overload requiring loop diuretics.

Methods: DCR is an on-going, prospective US registry of outpatient T2D patients from > 5000 cardiology, endocrinology, and primary care clinicians (current analysis used data from 2013-2019). Among T2D patients receiving loop diuretics, we examined the rate of chart documentation of heart failure. We used a 3-level hierarchical logistic regression model (patients nested within physician within practice) to examine factors associated with heart failure diagnosis.

Results: Among 1,322,640 adults with T2D, 225,125 (17.0%) were receiving a loop diuretic, of whom 91,969 (40.9%) had documentation of heart failure. Male sex, lower body mass index, atrial fibrillation, chronic kidney disease, and coronary artery disease were associated with greater odds of heart failure diagnosis. After accounting for patient factors, patients seen by cardiologists were the most likely to have HF documented followed by PCPs and then endocrinologists.

Conclusions: Among US outpatients with T2D, 17% of patients had evidence of volume overload-defined by loop diuretic prescription-of whom fewer than half had a clinical diagnosis of heart failure. While there may be non-heart failure indications for loop diuretics, our data suggest that a substantial proportion of T2D patients may have unrecognized heart failure and therefore could be missing opportunities for targeted therapies that could alter the clinical course of heart failure.

Citing Articles

Misdiagnosis of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus in Primary Care: A Report of Two Cases and Literature Review.

Yeshniyazov N, Posokhov I, Medovchshikov V, Kurmanalina G, Sartayeva A Vasc Health Risk Manag. 2024; 20:479-485.

PMID: 39512547 PMC: 11542475. DOI: 10.2147/VHRM.S489882.


Comparing prevalence and types of potentially inappropriate medications among patient groups in a post-acute and secondary care hospital.

Nakashima H, Ando H, Umegaki H Sci Rep. 2023; 13(1):14543.

PMID: 37714927 PMC: 10504332. DOI: 10.1038/s41598-023-41617-0.


Disparity in the Setting of Incident Heart Failure Diagnosis.

Sandhu A, Tisdale R, Rodriguez F, Stafford R, Maron D, Hernandez-Boussard T Circ Heart Fail. 2021; 14(8):e008538.

PMID: 34311559 PMC: 9070116. DOI: 10.1161/CIRCHEARTFAILURE.121.008538.

References
1.
Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

2.
White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

3.
Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

4.
Green C, Porter C, Bresnahan D, Spertus J . Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35(5):1245-55. DOI: 10.1016/s0735-1097(00)00531-3. View

5.
Morieri M, Longato E, Mazzucato M, Di Camillo B, Cocchiglia A, Gubian L . Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study. Cardiovasc Diabetol. 2019; 18(1):117. PMC: 6747737. DOI: 10.1186/s12933-019-0922-1. View